echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > New discovery of MM treatment: Aiming at cd229, use car-t to clear cancer cells!

    New discovery of MM treatment: Aiming at cd229, use car-t to clear cancer cells!

    • Last Update: 2020-02-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Compile newborn In the past two years, individualized car-t cell therapy has made great progress in the treatment of some leukemia and lymphoma, but scientists hope to apply this new technology to the second common blood cancer, multiple myeloma (mm), but there are some obstacles A new target called cd229 may help overcome these challenges, according to early evidence from a team at the huntsman Cancer Institute (HCI) at the University of Utah CD229 is a ubiquitous molecule on the surface of myeloma cells and myeloma stem cells, which can produce drug-resistant myeloma cells HCI team designed a human antibody targeting cd229, and created a car-t treatment method, using the antibody to target car-t to MM cells Research shows that the newly designed cd229 targets car-t to kill the myeloma cells in mm mouse model and the myeloma stem cells from MM patients The results were recently published in nature communications At present, a number of biopharmaceutical companies are competing to develop car-t therapy for mm, including pharmaceutical giant Johnson & Johnson Jnj-4528 is a car-t therapy targeting B cell mature antigen (BCMA) At the annual meeting of the American Society of Hematology held in December last year, Johnson & Johnson released the preliminary results of stage IB from the small Ib / stage II cartitude-1 study The data showed that among the patients with relapsed or refractory MM who had received multiple therapies in the past, jnj-4528 cleared the tumor in 69% of the patients A phase II study is planned to be completed by the end of this year At the meeting, Bluebird biology also released the clinical data of bb21217 for MM treatment, which is also a car-t cell therapy targeted at BCMA The data showed that 10 (83%) of the 12 evaluable patients receiving the lowest dose of treatment had tumor shrinking One of the unsettling problems with BCMA targeted cell therapies is whether they produce a sustained response The bb2121 early trial data released in May last year did not help alleviate this concern, as six of the 15 patients with complete remission eventually relapsed The HCI team turned its attention to cd229 and plans to improve response durability by eliminating myeloma stem cells As part of the study, the team collected samples from seven MM patients and compared their cd229 targeted car-t therapy with a BCMA targeted car-t therapy The results showed that compared with BCMA targeting car-t, cd229 targeting car-t significantly reduced MM cells and mm proliferating cells Dr djordje atanackovic, an associate professor at the University of Utah, said: "we believe that if we can target every cancer cell in MM patients, including cancer stem cells, it will produce key treatment differences, and make patients get a more lasting and deeper treatment response." HCI researchers plan to complete further studies to determine whether cd229 targeted car-t cells can be safely used in humans If safety is established, the team hopes to advance the treatment to clinical trials.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.